Abstract 1674P
Background
Nasopharyngeal carcinoma (NPC) can have implications on the sexual health of patients suffering from this cancer. This can be affected by various factors, whether it be the cancer itself, the treatments administered, or the associated psychological stress. However, sexual disorders are often overlooked in the management of these patients. The aim: is to assess the sexual health of patients with NPC at different stages of their treatment.
Methods
This is a descriptive analytical study evaluating sexual health in adult patients with NPC using EORTC SHQ-C22 Questionnaire. Thirty married patients were included between September and December 2023. The mean age was 45 years [32-68] with a sex ratio of 4 (24/6). Tumor stage (III) was the most represented (25 patients; 83.3%). The questionnaire was translated into colloquial Arabic and administered during treatment for 27 patients (71.4%), and within the first 6 months of follow-up for 3 patients. All patients resided at home with their spouses at the time of the questionnaire.
Results
According to the EORTC SHQ-C22 scale, 17 patients were not sexually active (not at all or a little) during treatment (56.6%) with a feeling of sexual satisfaction (often or quite often) in 17 patients (70.8%). Thirteen patients (43.3%) considered sexual activity to be enjoyable (often or quite often). A negative impact of fatigue and treatment on sexual activity was experienced by 14 patients (46.6%, often or quite often) and a feeling of inability to satisfy their partner was felt by 12 patients (7% a little, 10% often, and 73% quite often). Sexual activity was not painful for 26 patients (86.6%), and concerns about pain during sexual intercourse or intimate physical contact were not felt by 21 patients (70%). Discussion with a doctor about sexuality was absent in most cases (27 patients, 90%). Communication with the partner about sexuality was unsatisfactory in all patients (90% did not communicate and 10% communicated very little). The median score of the EORTC SHQ-C22 was 67 [30-75]. Among these patients, 7 patients (23.3%) wished to receive treatment for their sexuality, and no patient was using any specific sexual treatment.
Conclusions
The search for sexual disorders in patients with NPC is essential, for better quality of life.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institut National d'Oncologie Rabat.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11